GE HealthCare Reports Strong Q2 Results Amid Rising Diagnostic Equipment Demand
GE HealthCare Technologies Inc. (NASDAQ: GEHC) reported strong second-quarter results, with organic order growth of approximately 11% and a record book-to-bill ratio of 1.15x. This performance pushed the company's backlog to $23.9 billion as healthcare institutions begin investing in diagnostic equipment after years of delayed capital expenditures due to pandemic-related disruptions. The Pharmaceutical Diagnostics segment led growth with an impressive 14.6% organic revenue increase, driven by high demand for contrast media and radiopharmaceuticals used in complex scans. GE HealthCare's robust supply chain gives it a competitive edge over generic suppliers. The Advanced Imaging Solutions division also saw solid performance at 5% organic growth due to increased adoption of cardiovascular ultrasound and CT systems. Despite margin pressures from tariffs, taxes, and rising supply chain costs, the company maintains a strong balance sheet with a low payout ratio. GE HealthCare is now reviewing its underperforming Patient Care Solutions segment for potential strategic options including sale.
Tickers: $GEHC